Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.
Ying JingYong-Chang ZhangJing WangKunyan LiXue ChenJianfu HengQian GaoYouqiong YeZhao ZhangYaoming LiuYanyan LouSteven Hsesheng LinLixia DiaoHong LiuXiang ChenGordon B MillsLeng HanPublished in: Journal of the National Cancer Institute (2022)
We observed minimal sex-associated differences in irAEs among cancer patients who received immune checkpoint inhibitor therapy. It may be unnecessary to consider sex effects for irAE management in clinical practice.